The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations
Open accessAbstract
Galantamine hydrobromide, a promising acetylcholinesterase inhibitor is reported to be associated with cholinergic side effects. Its poor brain penetration results in lower bioavailability to the target site. With an aim to overcome these limitations, solid-lipid nanoparticulate formulation of galantamine hydrobromide was developed employing biodegradable and biocompatible components. The selected galantamine hydrobromide-loaded solid-lipid nanoparticles offered nanocolloidal with size lower than 100 nm and maximum drug entrapment 83.42 ± 0.63%. In vitro drug release from these spherical drug-loaded nanoparticles was observed to be greater than 90% for a period of 24 h in controlled manner. In vivo evaluations demonstrated significant memory restoration capability in cognitive deficit rats in comparison with naive drug. The developed carriers offered approximately twice bioavailability to that of plain drug. Hence, the galantamine hydrobromide-loaded solid-lipid nanoparticles can be a promising vehicle for safe and effective delivery especially in disease like Alzheimer's.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The maximum drug entrapment of these SLNs was ~83 %, with greater than 90% drug release in 24 h.”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [104]
In the citing paper
“Interestingly, SLNs loaded with galantamine hydrobromide demonstrated enhanced bioavailability (two times higher than that of the pure drug) and improved memory and cognition in animals.104”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
The Relationships Between Age, Sex, and the Incidence of Dementia and Alzheimer Disease
Gao, S., Hendrie, H. C., Hall, K. S., & Hui, S. L. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.809 · Cited by 782
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of drug targeting · doi:10.1080/10611860400015936 · Cited by 742
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 623
Potential of solid lipid nanoparticles in brain targeting.
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615
Manufactured nanoparticles: their uptake and effects on fish—a mechanistic analysis
Handy, R. D., Henry, T. B., Scown, T. M., Johnston, B. D., & Tyler, C. R. (2008) · Ecotoxicology · doi:10.1007/s10646-008-0205-1 · Cited by 447
Feng, S., & Huang, G. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00364-3 · Cited by 400
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363
Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303
Research works printed but not linked: 4
- Muller RH, 1993, Proc Int Symp Control Rel Bioact Mater, 20, 480
- Patel KB, 2010, J Chem Pharm Res, 2, 36
- Shi F, 2012, Int J Nanomedicine, 7, 2033
- Sruthi N, 2015, IJPCBS, 5, 63
Cited by
Sorted by citations
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Alzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 506
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061117 · Cited by 239
Metadata
- Authors
- Misra, S., Chopra, K., Sinha, V. R., & Medhi, B.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Panjab University (IN)
- Corresponding author
- Medhi, Bikash
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2015-09-25
- Volume
- 23
- Issue
- 4
- Pages
- 1434-1443
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W1867774233
- Cited by
- 136
- References
- 40
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 11 · 2023: 19 · 2022: 29 · 2021: 10 · 2020: 16 · 2019: 9 · 2018: 7 · 2017: 6 · 2016: 3
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Drug Delivery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sun Pharma
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- galantamine hydrobromide, solid lipid nanoparticles, brain drug delivery, acetylcholinesterase inhibitors, Alzheimer's disease, encapsulation efficiency, controlled drug release, cognitive impairment, bioavailability enhancement, nanocarriers
- MeSH terms
- Animals, Brain, Cholinesterase Inhibitors, Drug Carriers, Galantamine, Lipids, Drug Delivery Systems, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
